Another study investigated early tumor marker response and treatment response in patients with advanced HCC treated with LEN and concluded that the AFP levels of most patients had declined after 2 weeks, and by 4 weeks the group that had achieved a sustained reduction in AFP demonstrated a higher objective response [54]. This evidence concerns the gene AFP and hepatocellular carcinoma.